Press "Enter" to skip to content

Baltimore biotech company raises $32.5 million to continue pursuing cancer immunotherapy treatment

A Baltimore company in the second phase of a clinical trial for a cancer immunotherapy treatment, one that taps the body’s own immune system to fight disease, has secured $32.5 million in financing to continue developing its products. WindMIL Therapeutics, a Johns Hopkins spinoff company based…
Source: Sun

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: